AWARD
A -- Multicenter Program for Developing Treatments for Botulinum Neurotoxin Intoxication
- Notice Date
- 10/14/2015
- Notice Type
- Award Notice
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- 14CTRABOTIAA
- Archive Date
- 11/13/2015
- Point of Contact
- David Daniel, 301-619-2845
- E-Mail Address
-
US Army Medical Research Acquisition Activity
(david.r.daniel27.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Award Number
- W81XWH-14-C-0070-P00002
- Award Date
- 9/6/2015
- Awardee
- INSTITUTE OF ADVANCED SCIENCES INC. (078840377) <br> 78 FAUNCE CORNER RD STE 540 <br> DARTMOUTH, MA 02747
- Award Amount
- $75,000.00
- Line Number
- 0001, 0002
- Description
- The government has extended the period of performance on three Research and Development (R&D) contracts in support of a Defense Threat Reduction Agency (DTRA) consortium project. The project is Development of Medical Countermeasures for Botulinum Neurotoxin Intoxication Focused on Therapeutics and Neuroregenerative Medicines. DTRA has established a multicenter program in which directed research projects are submitted, evaluated and selected to sponsor a network of collaboration amongst researchers. Under the multicenter collaboration, three proposals were selected to be administered in coordination with U.S Army Medical Research Institute of Chemical Defense (USAMRICD) collaborators: a. Montclair State University (MSU): MSU is contributing to the botulinum drug discovery effort by synthesizing small molecule drug candidates for treatment of botulinum toxin exposure and optimizing their pharmaceutical properties. b. Institute of Advanced Sciences (IAS): IAS will support the efforts at the USAMRICD by performing high throughput screening (HTS) of natural product and small molecule libraries. c. Ossianix Inc: Ossianix will provide an alternative to traditional inhibitors by developing small single chain shark antibodies as potential inhibitors for catalytic activity. The reason for the extension through December 31, 2015 is to allow additional research for USAMRICD to complete the first cycle of this consortium effort. After discussions between the collaborating parties it was determined that additional time and funding would be needed obtain the necessary objectives prior to the next research cycle. Funding in the amount of $75,000 for MSU and $75,000 for the Institute of Advanced Sciences will be provided to complete the first cycle of the research. Ossianix will be receiving a completion date extension using the funding made available at the time of initial contract. The three research contracts will end on December 31, 2015. Research contracts to be performed in Fiscal Year 2016 to support the development of medical countermeasures will be addressed competitively through the U.S Army Medical Research and Materiel Command's (USAMRMC's) Broad Agency Announcement 15-1 See the following website for additional information. https://www.usamraa.army.mil/pages/Baa_Forms/index.cfm?
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/Awards/W81XWH-14-C-0070-P00002.html)
- Record
- SN03921269-W 20151016/151014234154-97e46f2bf561105592ab777e8bf9c439 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |